<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Reported-in-Senate" dms-id="A1" public-private="public" slc-id="S1-EHF25528-70R-0Y-VDC"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>119 S1041 RS: Affordable Prescriptions for Patients Act</dc:title>
<dc:publisher>U.S. Senate</dc:publisher>
<dc:date>2025-04-10</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">II</distribution-code><calendar>Calendar No. 44</calendar><congress>119th CONGRESS</congress><session>1st Session</session><legis-num>S. 1041</legis-num><current-chamber>IN THE SENATE OF THE UNITED STATES</current-chamber><action><action-date date="20250313">March 13, 2025</action-date><action-desc><sponsor name-id="S287">Mr. Cornyn</sponsor> (for himself, <cosponsor name-id="S341">Mr. Blumenthal</cosponsor>, <cosponsor name-id="S153">Mr. Grassley</cosponsor>, and <cosponsor name-id="S253">Mr. Durbin</cosponsor>) introduced the following bill; which was read twice and referred to the <committee-name committee-id="SSJU00" added-display-style="italic" deleted-display-style="strikethrough">Committee on the Judiciary</committee-name></action-desc></action><action stage="Reported-in-Senate"><action-date date="20250410">April 10, 2025</action-date><action-desc>Reported by <sponsor name-id="S153">Mr. Grassley</sponsor>, with amendments</action-desc><action-instruction>Omit the parts struck through and insert the parts printed in italic</action-instruction></action><legis-type>A BILL</legis-type><official-title>To amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes.</official-title></form><legis-body><section id="S1" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Affordable Prescriptions for Patients Act</short-title></quote>.</text></section><section id="idf4001843-0e80-476c-a259-add62323e751" changed="not-changed"><enum>2.</enum><header>Patent infringement<deleted-phrase reported-display-style="strikethrough">; Medicare Improvement Fund</deleted-phrase></header><subsection id="idaabfb7f5-5190-43f7-9247-abd1fcf496cd" changed="not-changed"><enum>(a)</enum><header>In general</header><text>Section 271(e) of title 35, United States Code, is amended—</text><paragraph id="id070c3407-d38a-42e1-9c09-53e090a19658" changed="not-changed"><enum>(1)</enum><text>in paragraph (2)<deleted-phrase reported-display-style="strikethrough">(C)</deleted-phrase>, in the flush text following <deleted-phrase reported-display-style="strikethrough">clause</deleted-phrase><added-phrase reported-display-style="italic">subparagraph (C)</added-phrase>(ii), by adding at the end the following: <quote>With respect to a submission described in <deleted-phrase reported-display-style="strikethrough">clause</deleted-phrase><added-phrase reported-display-style="italic">subparagraph (C)</added-phrase>(ii), the act of infringement shall extend to any patent that claims the biological product, a method of using the biological product, or a method or product used to manufacture the biological product.</quote>; and</text></paragraph><paragraph id="idbb5fe4e6-6c61-4fb8-8ce7-f6462b3c857f" changed="not-changed"><enum>(2)</enum><text>by adding at the end the following:</text><quoted-block style="OLC" display-inline="no-display-inline" id="id9d80d949-7c92-4e38-8930-35c2d8834efb" changed="not-changed"><paragraph id="idef379089-ab6c-43cd-aacb-1b813a4c049b" indent="up1" changed="not-changed"><enum>(7)</enum><subparagraph commented="no" display-inline="yes-display-inline" id="id637a63c7-7755-430e-91da-37e9045becdd" changed="not-changed"><enum>(A)</enum><text>Subject to subparagraphs (C), (D), and (E), if the sponsor of an approved application for a reference product, as defined in section 351(i) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262(i)</external-xref>) (referred to in this paragraph as the <quote>reference product sponsor</quote>), brings an action for infringement under this section against an applicant for approval of a biological product under section 351(k) of such Act that references that reference product (referred to in this paragraph as the <quote>subsection (k) applicant</quote>), the reference product sponsor may assert in the action a total of not more than 20 patents of the type described in subparagraph (B), not more than 10 of which shall have issued after the date specified in section 351(l)(7)(A) of such Act.</text></subparagraph><subparagraph id="id48fe4f6c-44eb-44ac-913c-6b62e667b68f" indent="up1" changed="not-changed"><enum>(B)</enum><text>The patents described in this subparagraph are patents that satisfy each of the following requirements:</text><clause id="idda7970cf-25ca-441b-bfd3-98dbcad89e13" changed="not-changed"><enum>(i)</enum><text>Patents that claim the biological product that is the subject of an application under section 351(k) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262(k)</external-xref>) (or a use of that product) or a method or product used in the manufacture of such biological product.</text></clause><clause id="idcc501db4-ba52-4667-a668-1f4245e910c2" changed="not-changed"><enum>(ii)</enum><text>Patents that are included on the list of patents described in paragraph (3)(A) of section 351(l) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262(l)</external-xref>), including as provided under paragraph (7) of such section 351(l).</text></clause><clause id="idfc7cff7b-2d68-4d36-8ee8-6c36de51c537" changed="not-changed"><enum>(iii)</enum><text>Patents that—</text><subclause id="idf68925ff-bc31-4c27-8ad9-e4d5b0185272" changed="not-changed"><enum>(I)</enum><text>have an actual filing date of more than 4 years after the date on which the reference product is approved; or</text></subclause><subclause id="id4f303e38-f70c-4940-ad97-b5995b06b217" changed="not-changed"><enum>(II)</enum><text>include a claim to a method in a manufacturing process that is not used by the reference product sponsor.</text></subclause></clause></subparagraph><subparagraph id="id89271ed9-191d-45d0-9193-6d8317daf5b4" indent="up1" changed="not-changed"><enum>(C)</enum><text>The court in which an action described in subparagraph (A) is brought may increase the number of patents limited under that subparagraph—</text><clause id="id750cf6d1-546e-43f5-ac3f-89ec769cd9da" changed="not-changed"><enum>(i)</enum><text>if the request to increase that number is made without undue delay; and</text></clause><clause id="id0871c220-4053-475a-8ec1-48f322108ae0" changed="not-changed"><enum>(ii)</enum><subclause commented="no" display-inline="yes-display-inline" id="id5fc77df1-2346-4004-b0c3-6a3a0627e94b" changed="not-changed"><enum>(I)</enum><text>if the interest of justice so requires; or</text></subclause><subclause id="idaefdfcd3-e204-420a-a452-2ce193be21bd" indent="up1" changed="not-changed"><enum>(II)</enum><text>for good cause shown, which—</text><item id="idcd403146-4a4b-4b03-aa8c-f7f893410ecb" changed="not-changed"><enum>(aa)</enum><text>shall be established if the subsection (k) applicant fails to provide information required by section 351(k)(2)(A) of the Public Health Service Act (42. U.S.C. 262(k)(2)(A)) that would enable the reference product sponsor to form a reasonable belief with respect to whether a claim of infringement under this section could reasonably be asserted; and</text></item><item id="id0a079ea1-451c-4ab2-84ae-5ce29729f3d4" changed="not-changed"><enum>(bb)</enum><text>may be established—</text><subitem id="idd2ce5293-5e93-4661-a4ac-da2623d5bdb5" changed="not-changed"><enum>(AA)</enum><text>if there is a material change to the biological product (or process with respect to the biological product) of the subsection (k) applicant that is the subject of the application;</text></subitem><subitem id="ide1992154-dd3e-4add-81d4-180b4862ecc4" changed="not-changed"><enum>(BB)</enum><text>if, with respect to a patent on the supplemental list described in section 351(l)(7)<deleted-phrase reported-display-style="strikethrough">(A)</deleted-phrase> of <added-phrase reported-display-style="italic">the</added-phrase> Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262(l)(7)</external-xref><deleted-phrase reported-display-style="strikethrough">(A)</deleted-phrase>), the patent would have issued before the date specified in <deleted-phrase reported-display-style="strikethrough">such</deleted-phrase> section 351(l)(7)(A) <added-phrase reported-display-style="italic">of such Act</added-phrase> but for the failure of the Office to issue the patent or a delay in the issuance of the patent, as described in paragraph (1) of section 154(b) and subject to the limitations under paragraph (2) of such section 154(b); or</text></subitem><subitem id="id4245a3ff-e179-4f29-a07d-e3b652904602" changed="not-changed"><enum>(CC)</enum><text>for another reason that shows good cause, as determined appropriate by the court.</text></subitem></item></subclause></clause></subparagraph><subparagraph id="id7c489a23-6d2d-4734-bb18-149ac7c799b5" indent="up1" changed="not-changed"><enum>(D)</enum><text>In determining whether good cause has been shown for the purposes of subparagraph (C)(ii)(II), a court may consider whether the reference product sponsor has provided a reasonable description of the identity and relevance of any information beyond the subsection (k) application that the court believes is necessary to enable the court to form a belief with respect to whether a claim of infringement under this section could reasonably be asserted.</text></subparagraph><subparagraph id="id901cc588-255a-426d-a548-305cd57aeae0" indent="up1" changed="not-changed"><enum>(E)</enum><text>The limitation imposed under subparagraph (A)—</text><clause id="id1325514c-0c76-49ba-b8b7-4b92d233e2d3" changed="not-changed"><enum>(i)</enum><text>shall apply only if the subsection (k) applicant completes all actions required under paragraphs (2)(A), (3)(B)(ii), (5), (6)(C)(i), (7), and (8)(A) of section 351(l) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262(l)</external-xref>); and</text></clause><clause id="id0caa9ced-5125-424d-abca-f402c50262d1" changed="not-changed"><enum>(ii)</enum><text>shall not apply with respect to any patent that claims, with respect to a biological product, a method for using that product in therapy, diagnosis, or prophylaxis, such as an indication or method of treatment or other condition of use.</text></clause></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection><subsection id="id11f6f701-fe42-4a3d-8c48-1de7a62d8b22" changed="not-changed" commented="no" display-inline="no-display-inline"><enum>(b)</enum><header>Applicability</header><text>The amendments made by subsection (a) shall apply with respect to an application submitted under section 351(k) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262(k)</external-xref>) on or after the date of enactment of this Act.</text></subsection></section></legis-body><endorsement><action-date date="20250410">April 10, 2025</action-date><action-desc>Reported with amendments</action-desc></endorsement></bill> 

